Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Monte Rosa Therapeutics, Inc.

NASDAQ: GLUE · Life Sciences · 3 alerts · CIK 1826457

Share price
$9.16Close, Nov 16
Market cap
$783M
Shares outstanding
85.45MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Monte Rosa Therapeutics, Inc. filings on SEC EDGAR ↗

7:14 AM ET 10-Q
Financial Results

Monte Rosa Therapeutics Q3 2026 Results: Turns Profitable, Net Income $3.06M

Monte Rosa Therapeutics reported a net loss of $84.8 million for the nine months ended September 30, 2026, compared to a net income of $7.5 million in the prior year period, primarily due to lower collaboration revenue. The company significantly strengthened its balance sheet through an underwritten public offering that raised $323.8 million, ending the period with $577.7 million in cash, cash equivalents, and marketable securities.

Key figure
Net income $3.06M
7:08 AM ET 8-K
Financial Results

Monte Rosa Therapeutics Financial Results

Monte Rosa Therapeutics reported Q3 2026 financial results, highlighting a cash position of $582.6 million and $87.5 million in milestone payments triggered by Novartis initiating Phase 2 studies for MRT-6160. The company also announced positive Phase 1 data for MRT-8102 in cardiovascular disease and the initiation of multiple Phase 2 clinical trials across its pipeline.

Counterparty
Novartis
Term
3 months

“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

“We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.